The effects of Chinese proprietary medicine and vaccination on patients with COVID-19: a retrospective study in Macao.

ABSTRACT:

Background

COVID-19 is continuing to ravage globally and has resulted in a huge health and financial burden. Chinese proprietary medicines, such as Lianhua Qingwen (LHQW) and Huoxiang Zhengqi (HXZQ) capsules, have been recommended for non-high-risk patients with COVID-19 in China. Based on this, we described the baseline information, using status of LHQW and HXZQ capsules and inoculation history of quarantined patients in the second half of 2022 in Macao. Additionally, we analyzed the underlying association among medicines administration, vaccination and COVID-19 indices, in order to explore novel clues for the regular control and prevention of local epidemic situation in the future.

Methods

A total of 976 patients in Macao quarantine hotels from June to August 2022 were inc

SUBMITTER: Mo H 

PROVIDER: S-EPMC10807168 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature